New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AIM ImmunoTech Inc. (AIM) vs Alzamend Neuro, Inc. (ALZN)

AIM ImmunoTech Inc. and Alzamend Neuro, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Alzamend Neuro, Inc. are of similar size ($4.9M and $4.8M). Alzamend Neuro, Inc. has the higher net margin (0.00% vs −15,526.4%) and the higher return on invested capital (0.00% vs −5,687.5%). Across the 14 metrics below, Alzamend Neuro, Inc. leads on 11 and AIM ImmunoTech Inc. on 3.

Valuation

Metric AIM ALZN Biotechnology median
P/E n/m n/m 8.26
P/S 42.85 n/m 9.20
P/B 0.55 0.79 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.26 0.30 0.67
EV/Sales (28.62) n/m 9.05
Earnings yield (2,206.08%) (225.49%) (34.24%)
Free cash flow yield (322.03%) (156.37%) (24.77%)

Profitability

Metric AIM ALZN Biotechnology median
Gross margin 38.46% 0.00% 70.18%
Operating margin (12,800.00%) 0.00% 0.00%
Net margin (15,526.37%) 0.00% 0.00%
Free cash flow margin (13,792.31%) 0.00% 0.00%
Return on equity (2,828.63%) (163.23%) (51.58%)
Return on assets (185.36%) (122.36%) (45.91%)
Return on invested capital (5,687.50%) 0.00% 0.00%

Growth

Metric AIM ALZN Biotechnology median
Revenue growth (TTM) (18.75%) — 7.20%
EPS growth (last fiscal year) 72.19% 76.77% 29.04%
Revenue growth, 5-year CAGR (11.60%) — 9.48%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM ALZN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.75 3.01 4.83
Net debt to EBITDA 0.22 0.08 1.01

Dividend

Metric AIM ALZN Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric AIM ALZN Biotechnology median
Market cap 4.79m 4.92m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack